(alphaS)-alpha-Amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]benzenepropanamide hydrochloride - Names and Identifiers
Name | Bortezomib intermediates II
|
Synonyms | Bortezomib intermediates I Bortezomib Intermediate II Bortezomib Impurity 54 HCl BortezoMib InterMediate II Bortezomib intermediates II BortezoMib interMediates N-2 N-[(1S)-1-benzyl-2-({(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0~2,6~]dec-4-yl]butyl}amino)-2-oxoethyl] (S)-2-amino-N-((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)-3-phenylpropanamide hydrochloride (αS)-α-Amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]-benzenepropanamide Monohydrochloride (alphaS)-alpha-Amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]benzenepropanamide hydrochloride
|
CAS | 205393-21-1
|
(alphaS)-alpha-Amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]benzenepropanamide hydrochloride - Physico-chemical Properties
Molecular Formula | C24H38BClN2O3
|
Molar Mass | 448.83412 |
Melting Point | 197-198℃ |
Storage Condition | Inert atmosphere,Store in freezer, under -20°C |
Use | Intermediate |
(alphaS)-alpha-Amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]benzenepropanamide hydrochloride - Introduction
Bortezomib is an anticancer drug, and its Intermediate 2 refers to the intermediate compound of Bortezomib. The following is a description of the nature, use, formulation and safety information of Bortezomib intermediaries II:
Nature:
Bortezomib intermediates II is a white or off-white solid with high chemical stability.
Use:
Bortezomib intermediates II is mainly used as a synthetic intermediate of Bortezomib, used to prepare Bortezomib as a drug for the treatment of multiple myeloma and non-Hodgkin's lymphoma. Bortezomib inhibits the growth and proliferation of cancer cells by inhibiting the function of the proteasome.
Method:
The preparation of Bortezomib intermediates II usually involves multiple steps of chemical synthesis. The specific preparation method is usually confidential and carried out by professionals in the laboratory.
Safety Information:
For the safety information of Bortezomib intermediates II, because there are no clear research results for Intermediate 2, the toxicity and safety data are relatively limited. However, bortezomib as a drug has been studied and used in clinic, and has certain side effects and safety risks. When using bortezomib, it needs to be evaluated and monitored by a professional doctor according to the specific condition and the patient's physical condition to ensure the safety and rational use of drugs. At the same time, the relevant medication guidelines and precautions should be followed to avoid potential drug interactions and adverse reactions.
Last Update:2024-04-09 21:04:16